Content area
Full Text
Pressure is building to take a deeper dive into the cancer risks of incretin mimetics, a group of drugs for Type 2 diabetes that includes blockbusters like Merck's ($MRK) Januvia and Novo Nordisk's ($NVO) Victoza .
A study of insurance records in March raised the specter of higher pancreatic cancer risks, and the FDA has been taking a closer look at the data. Drugmakers are meeting this week with officials of the FDA and the National Institutes of Health to present safety data for their drugs and to discuss what further study may be needed. FDA spokeswoman Morgan Liscinsky told Bloomberg that one possibility is a large clinical trial...